JP2013518869A - 呼吸器疾患の治療 - Google Patents

呼吸器疾患の治療 Download PDF

Info

Publication number
JP2013518869A
JP2013518869A JP2012551685A JP2012551685A JP2013518869A JP 2013518869 A JP2013518869 A JP 2013518869A JP 2012551685 A JP2012551685 A JP 2012551685A JP 2012551685 A JP2012551685 A JP 2012551685A JP 2013518869 A JP2013518869 A JP 2013518869A
Authority
JP
Japan
Prior art keywords
composition
oil
day
nsaid
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012551685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518869A5 (enExample
Inventor
ウィルソン カッパロス−ワンダレイ、
ジョン ブリュー、
グレゴリー ストロフ、
ロビン マーク バニスター、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocopea Ltd
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1001912.3A external-priority patent/GB201001912D0/en
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of JP2013518869A publication Critical patent/JP2013518869A/ja
Publication of JP2013518869A5 publication Critical patent/JP2013518869A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012551685A 2010-02-05 2011-02-04 呼吸器疾患の治療 Pending JP2013518869A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1001912.3A GB201001912D0 (en) 2010-02-05 2010-02-05 Treatment of respiratory disorders
GB1001912.3 2010-02-05
GB1015878.0 2010-09-22
GB1015878A GB2477590A (en) 2010-02-05 2010-09-22 A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
PCT/GB2011/050189 WO2011095814A1 (en) 2010-02-05 2011-02-04 Treatment of respiratory disorders

Publications (2)

Publication Number Publication Date
JP2013518869A true JP2013518869A (ja) 2013-05-23
JP2013518869A5 JP2013518869A5 (enExample) 2014-03-20

Family

ID=43927856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012551685A Pending JP2013518869A (ja) 2010-02-05 2011-02-04 呼吸器疾患の治療

Country Status (13)

Country Link
US (1) US20130178448A1 (enExample)
EP (1) EP2531188A1 (enExample)
JP (1) JP2013518869A (enExample)
CN (1) CN102858333A (enExample)
AU (1) AU2011212256A1 (enExample)
CA (1) CA2788766A1 (enExample)
GB (1) GB2477590A (enExample)
MX (1) MX2012009052A (enExample)
NZ (1) NZ601594A (enExample)
RU (1) RU2012137785A (enExample)
SG (2) SG10201500899VA (enExample)
WO (1) WO2011095814A1 (enExample)
ZA (1) ZA201205829B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544802A (ja) * 2010-10-29 2013-12-19 バイオコピア リミテッド 炎症性疾患

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2013049749A2 (en) 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
EP2704696A1 (en) 2012-03-26 2014-03-12 Glatt AG Taste-masked ibuprofen granules
CN103893171B (zh) * 2014-04-19 2016-05-25 武汉胜达康生物科技有限公司 盐酸苄达明在制备治疗或预防流感病毒感染药物中的应用
US20150343139A1 (en) * 2014-05-30 2015-12-03 Boston Scientific Scimed, Inc. Implantable pumps and related methods of use
AR102172A1 (es) 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
CN109464670B (zh) * 2017-09-08 2022-08-02 中国科学院微生物研究所 调控a型和b型流感病毒核蛋白出核的关键氨基酸位点及其作为抗流感病毒药物靶点的用途
KR20220158031A (ko) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
US12324853B2 (en) 2020-08-10 2025-06-10 Quimica Luar S.R.L. Methods for treating respiratory viral infections
WO2022119756A1 (en) * 2020-12-04 2022-06-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection
WO2026029291A1 (ko) * 2024-08-01 2026-02-05 주식회사 배젠 신규한 화합물을 유효성분으로 포함하는 만성폐쇄성폐질환 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02502719A (ja) * 1987-03-05 1990-08-30 ザ　リポソーム　カンパニー，インコーポレイテッド 薬理学的剤‐脂質溶液製剤
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH069381A (ja) * 1992-03-26 1994-01-18 Toyo Capsule Kk イブプロフェン含有軟カプセル剤
JPH06507404A (ja) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4571400A (en) * 1984-12-18 1986-02-18 Belleview Pharmaceutical, Inc. Dihydrocodeine/ibuprofen pharmaceutical compositions and method
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US4918103A (en) * 1988-07-25 1990-04-17 Formulations Development Labs Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
AU6390096A (en) * 1995-07-20 1997-02-18 Pharmacia & Upjohn Company Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ATE414542T1 (de) * 2000-12-19 2008-12-15 Univ Texas Nsaid zusammensetzungen enthaltend lecithinöl zum schutz des magen-darm-traktes und zur erhöhten therapeutischen wirkung
AU2002255190A1 (en) * 2001-04-10 2002-10-28 Fakhreddin Jamali Composition for enhanced absorption of nsaids
JP5137289B2 (ja) * 2001-08-03 2013-02-06 武田薬品工業株式会社 安定な乳化組成物
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
JP2005539089A (ja) * 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
ES2270361T3 (es) * 2003-03-20 2007-04-01 Pharmacia Corporation Formulacion dispersable de un agente antiinflamatorio.
JP2007500691A (ja) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗炎症剤の分散性製剤
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US20050152968A1 (en) * 2004-01-09 2005-07-14 Brophy Kristine M. Microemulsions for pharmaceutical compositions
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
MX2009000145A (es) * 2006-06-30 2009-01-23 Mcneil Ppc Inc Capsulas duras llenas con liquido que contiene ibuprofeno.
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
WO2009069139A1 (en) * 2007-11-28 2009-06-04 Alkem Laboratories Ltd. Dosage form providing an ibuprofen-containing liquid fill
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
NZ592984A (en) * 2008-11-19 2012-12-21 Merial Ltd Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
JP2012519160A (ja) * 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する組み合わせ薬
WO2010097332A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02502719A (ja) * 1987-03-05 1990-08-30 ザ　リポソーム　カンパニー，インコーポレイテッド 薬理学的剤‐脂質溶液製剤
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH06507404A (ja) * 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
JPH069381A (ja) * 1992-03-26 1994-01-18 Toyo Capsule Kk イブプロフェン含有軟カプセル剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015003471; 田中千賀子他編，　ＮＥＷ薬理学，　２００２，　ｐ．４８４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544802A (ja) * 2010-10-29 2013-12-19 バイオコピア リミテッド 炎症性疾患

Also Published As

Publication number Publication date
NZ601594A (en) 2014-10-31
EP2531188A1 (en) 2012-12-12
ZA201205829B (en) 2013-05-29
AU2011212256A1 (en) 2012-08-23
RU2012137785A (ru) 2014-03-10
US20130178448A1 (en) 2013-07-11
SG10201500899VA (en) 2015-04-29
GB2477590A (en) 2011-08-10
GB201015878D0 (en) 2010-10-27
CN102858333A (zh) 2013-01-02
SG183176A1 (en) 2012-09-27
CA2788766A1 (en) 2011-08-11
MX2012009052A (es) 2012-11-29
WO2011095814A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
US20130178448A1 (en) Treatment of Respiratory Disorders
CN103282021A (zh) 炎症性疾病
ES2881885T3 (es) Composiciones que comprenden una mezcla de aceites de ácidos grasos que comprende EPA y DHA en forma de ácido libre y un tensioactivo, y procedimientos y usos de las mismas
RU2680801C2 (ru) Композиции и способы для лечения хронического воспаления и воспалительных заболеваний
US9149424B2 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
US20100016262A1 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
CN103608023A (zh) 磷虾油的胃肠外治疗应用
JP2004269528A (ja) ヘルペスウイルス感染により引き起こされる疼痛又は炎症の緩和に有効な局所皮膚適用製剤
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
KR20190073365A (ko) 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
FR2959936A1 (fr) Composition nasales a visee systemique a base de cocoyl proline ou d 'au moins un de ses constituants
CN112789059A (zh) 氨基酸类营养素的应用以及包含它的药物组合物
TW201521719A (zh) 含有脂質化合物、三酸甘油酯及界面活性劑之組成物與使用該組成物之方法
CN113164420A (zh) 治疗组合物
CN102655859A (zh) 病毒感染的组合疗法治疗
JP2024129109A (ja) トリグリセリドの固体組成物及びその使用
KR20200089283A (ko) 점막 감염을 치료하기 위한 에멀젼
JP2019518798A (ja) リポヌクレオチドに基づくａｒｄｓの治療
CN102740845A (zh) 微生物感染的治疗
RU2582278C2 (ru) Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, способ его получения и комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
JP2022543695A (ja) Ｏｔｃ及び医薬品のバイオアベイラビリティを増加する方法
WO2008038423A1 (fr) Composition antiphlogistique et analgésique pour une utilisation orale
CN110139645A (zh) 用于预防和/或治疗恶病质的ω-3脂肪酸组合物
ES3037731T3 (en) Composition to prevent intestinal damage
CN101485679B (zh) 一种预防和治疗高血脂的药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027